C

    Chemomab Therapeutics Ltd DRC (CMMB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.72
    +0.01 (+0.37%)

    Market Cap: $19.86M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(21/29)
    Avg Surprise
    -82.13%
    Streak
    8 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.00
    Range$0.00 - $0.00
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.01+0.0%
    60d ago$-0.01+0.0%
    30d ago$0.00+0.0%
    7d ago$0.00+0.0%
    Current$0.00
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$0.00---
    Jun 26
    		$-1.40$0.00N/AMiss-6900.0%
    Mar 26
    		$-0.00$0.00N/AMiss+97.9%
    Dec 25
    		$-0.00N/A+70.00%Beat+62.5%
    Sep 25
    		$-0.00N/A+90.00%Beat+90.0%
    Jun 25
    		$-0.02$-0.04+50.00%Beat-140.0%
    Mar 25
    		$-0.14$-0.20+30.00%Beat-133.3%
    Dec 24
    		$-0.01$-0.01+20.00%Beat+97.0%
    Sep 24
    		$-0.04$-0.04+0.00%Beat+42.9%
    Jun 24
    		$0.05$-0.04+225.00%Beat+135.7%
    Mar 24
    		$-0.06$-0.06+0.00%Beat+62.5%
    Dec 23
    		$-0.27$-0.02-1227.00%Miss-89.6%
    Sep 23
    		$-0.07$-0.08+12.50%Beat+50.0%
    Jun 23
    		$-0.14$-0.16+12.50%Beat-27.3%
    Mar 23
    		$-0.16$-0.14-14.29%Miss-77.8%
    Dec 22
    		$-0.14$-0.12-16.67%Miss+68.2%
    Sep 22
    		$-0.14N/A+84.78%Beat-180.0%
    Jun 22
    		$-0.11N/A+84.72%Beat-120.0%
    Mar 22
    		$-0.09N/A+86.76%Beat-125.0%
    Dec 21
    		$-0.44$-0.10-340.00%Miss-633.3%
    Sep 21
    		$-0.05$-0.06+16.67%Beat+44.4%
    Jun 21
    		$-0.05N/A+89.13%Beat+44.4%
    Mar 21
    		$-0.04N/A+97.67%Beat+99.5%
    Dec 20
    		$-0.06N/A+96.25%Beat-100.2%
    Sep 20
    		$-0.09$-0.09+0.00%Beat+99.7%
    Jun 20
    		$-0.09$-0.11+18.18%Beat+97.8%
    Mar 20
    		$-8.00$-1.84-334.78%Miss+85.7%
    Dec 19
    		$31.20$-2.00+1660.00%Beat+26100.0%
    Sep 19
    		$-34.40$-2.93-1074.06%Miss-
    Jun 19
    		$-4.00$-2.64-51.52%Miss-
    Mar 19
    		$-56.00$-2.56-2087.50%Miss-
    Dec 18
    		$-0.12$-0.15+20.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.93EV/EBITDA0.33x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-82.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.41xQuick Ratio6.41x
    Trading Statistics
    Beta0.66Avg Volume101.81K
    52-Week High$3.5852-Week Low$1.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.34
    SMA 20$2.10
    SMA 50$1.83
    SMA 200$1.84
    EMA 10$2.41
    EMA 20$2.18
    EMA 50$1.94
    EMA 200$2.14

    MACD

    Line: 0.25Signal: 0.17Hist: 0.08

    ADX

    ADX: 49.5+DI: 42.8-DI: 4.7

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$2.49

    Bollinger Bands

    Upper Band$2.77
    Lower Band$1.44
    %B Position6340%(Upper)
    Band Width0.96

    RSI (14-Day)

    Overbought
    83.4

    Momentum Oscillators

    Stoch %K76.5
    Stoch %D81.5
    Williams %R-23.4
    ROC (10d)41.7%
    Momentum0.80
    CCI (20d)157.7
    MFI (14d)87.1

    Volatility Measures

    ATR (14d)$0.19(6.9%)
    StdDev (20d)0.33
    Hist Vol61.3%(High)

    Volume Flow

    VWAP$2.72
    OBV-3.3M
    AD Line1.5B
    CMF (20d)0.197

    Volume Metrics

    Avg Vol (20d)103.0K
    Vol Ratio0.4x(Low)
    VWMA (20d)$2.31

    Pivot Points

    R3$3.13
    R2$3.00
    R1$2.86
    Pivot Point$2.73
    S1$2.59
    S2$2.46
    S3$2.32

    Advanced Oscillators

    TSI50.86
    Ultimate Osc56.7
    KST394.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/A$33,687N/AN/AN/A$26,901N/A$16,173$18,938
    Gross ProfitN/AN/AN/AN/A$-33,687N/AN/AN/A$-26,901N/A$-16,173$-18,938
    Operating Expenses$2.28M$1.85M$1.99M$1.84M$2.26M$3.49M$3.21M$3.71M$3.77M$4.05M$3.85M$4.33M
    R&D$1.16M$925,000$1.10M$960,000$1.29M$2.49M$2.41M$2.84M$2.93M$3.15M$3.11M$3.35M
    SG&A$0$925,000$881,000$884,000$975,000$994,000$802,000$874,000$840,000$896,000$751,000$990,000
    Operating Income$-2,279,481$-1,850,000$-1,986,330$-1,844,000$-2,262,000$-3,487,000$-3,213,000$-3,710,000$-3,768,000$-4,048,000$-3,848,000$-4,367,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$500$1,996$0$0
    Income Before Tax$-2,202,176$-1,773,000$-1,884,699$-1,742,000$-2,057,000$-3,323,000$-2,963,000$-3,483,000$-3,631,000$-3,868,000$-3,454,000$-4,136,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-2$-16,751$-1$-54,822
    Net Income$-2,202,176$-1,773,000$-1,884,699$-1,742,000$-2,057,000$-3,323,000$-2,963,000$-3,483,000$-3,631,000$-3,868,000$-3,454,000$-4,068,000
    EBITDA$-2,279,481$-1,832,500$-1,974,000$-1,830,750$-2,245,500$-3,473,750$-3,196,250$-3,693,250$-3,754,500$-4,031,250$-3,831,827$-4,348,062
    EBITN/A$-1,850,000$-1,984,368$-1,844,000$-2,262,000$-3,487,000$-3,213,000$-3,710,000$-3,768,000$-4,048,000$-3,848,000$-4,367,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CMMB

    News

    Chemomab Therapeutics, Scipher Medicine Expect Merger to Close Before End of 2026

    Chemomab Therapeutics and Scipher Medicine anticipate their merger to be finalized before the end of 2026. This announcement highlights the companies' strategic move to combine operations. The merger is expected to bring together their respective strengths in the biotechnology and precision medicine sectors.

    Moomoo•8/20/26•
    Neutral

    Chemomab (CMMB) flags going‑concern risk, lines up Scipher deal

    Chemomab Therapeutics (CMMB) reported a net loss of $3.94 million for the first half of 2026 and flagged substantial doubt about its ability to continue as a going concern without new funding. The company has entered a definitive merger agreement with Scipher Medicine, which includes a $30 million PIPE investment, to advance nebokitug into a Phase 2 trial for rheumatoid arthritis. The merger is expected to close by year-end 2026, with current Chemomab shareholders projected to own about 32% of the combined entity and receive contingent value rights related to nebokitug milestones.

    Stock Titan•8/19/26•
    Neutral

    Chemomab Q2 Results: Net loss widens to $2.2M, cash drops to $6.7M

    Chemomab Therapeutics reported a Q2 2026 net loss per share of $(0.24), missing analyst estimates, and saw its cash reserves decrease to $6.7 million, though it expects to fund operations into early 2027. The company is advancing an all-stock merger with Scipher Medicine, valued at $150 million pre-placement, which is anticipated to close by year-end and aims to progress a Phase 2 clinical trial for nebokitug in rheumatoid arthritis. Despite a slight reduction in R&D expenses, a marginal increase in G&A costs contributed to the widened net loss.

    scanx.trade•8/19/26•
    Bearish

    Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

    Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update, primarily focusing on its proposed merger with Scipher Medicine. The merger aims to advance nebokitug, a first-in-class CCL24-blocker, into a Phase 2 precision medicine trial for rheumatoid arthritis, a significant market with unmet needs. The combined company is valued at $150 million and is expected to have sufficient cash through the Phase 2 trial readout.

    GlobeNewswire•8/19/26•
    Bullish

    Chemomab Therapeutics (CMMB) gains 5.2% stake holder in Touchstone Global

    Touchstone Global Investments Pty Ltd has reported a 5.2% passive stake in Chemomab Therapeutics Ltd. (CMMB), holding 377,814 American Depositary Shares (ADSs). This disclosure, filed on a Schedule 13G, indicates that Touchstone Global has sole voting and dispositive power over these shares, with each ADS representing 80 ordinary shares. The filing signals a significant, yet passive, ownership interest by the Australian investment firm in the biotechnology company.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About CMMB

    Does CMMB pay dividends?
    Chemomab Therapeutics Ltd DRC (CMMB) does not currently pay a regular dividend.
    What is CMMB's market cap?
    Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalization of $19.86M with a current stock price of $2.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In